LYMPHANGIOLEIOMYOMATOSIS AND SIROLIMUS: MEDIUM-TERM IMPACT ON PULMONARY FUNCTION
M. Garcia Moyano (Barakaldo, Spain), A. Urrutia (Barakaldo, Spain), L. Serrano (Barakaldo, Spain), A. Gómez (Barakaldo, Spain), S. Castro (Barakaldo, Spain), I. González (Barakaldo, Spain), J. Solorzano (Barakaldo, Spain), C. Jaca (Barakaldo, Spain), P. Ansola (Barakaldo, Spain), M. Iriberri (Barakaldo, Spain)
Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Garcia Moyano (Barakaldo, Spain), A. Urrutia (Barakaldo, Spain), L. Serrano (Barakaldo, Spain), A. Gómez (Barakaldo, Spain), S. Castro (Barakaldo, Spain), I. González (Barakaldo, Spain), J. Solorzano (Barakaldo, Spain), C. Jaca (Barakaldo, Spain), P. Ansola (Barakaldo, Spain), M. Iriberri (Barakaldo, Spain). LYMPHANGIOLEIOMYOMATOSIS AND SIROLIMUS: MEDIUM-TERM IMPACT ON PULMONARY FUNCTION. 2372
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: